Director, Immunoassay Development

Ph.D. in Biochemistry, Immunology, Analytical Chemistry, Biological Sciences, or a related field (or equivalent experience) with a minimum of 10 years of experience. Other combinations of education and/or experience may be considered.

Significant hands-on experience developing immunoassays within vaccine CMC, analytical development, or other regulated laboratory environments.

Expert-level, hands-on experience with MSD (Meso Scale Discovery) or closely related immunoassay platforms, including method development, optimization, troubleshooting, and lifecycle support.

Direct experience with conjugated vaccines, including polysaccharide–protein conjugates.

Solid understanding of protein chemistry and conjugation chemistry, particularly as applied to biological drug and vaccine development.

Demonstrated expertise in potency and antigenicity assays supporting vaccine release, stability, and comparability.

The compensation package will be competitive and includes comprehensive benefits and an equity component.

$213,000 – $250,000 *(SF Bay Area). Salary ranges for non-California locations may vary.

We are an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, disability or veteran status.

Establish and lead a new Immunoassay Development function within Analytical Development, defining scope, strategy, and operating model aligned with CMC and program needs.

For VAX-31, partner closely with current immunoassay leadership to learn and internalize the full development history, scientific rationale, and performance characteristics of the existing MSD-based immunoassay platform.

Serve as scientific steward for the VAX-31 immunoassay, providing troubleshooting, root-cause analysis, and technical problem-solving support to Quality Control (QC) and Analytical Sciences and Technology (ASAT) teams.

Support ASAT activities for VAX-31, including qualification, lifecycle management, and change control of critical immunoassay reagents.

Develop and execute immunoassay strategies to support potency, antigenicity, identity, and trace-level impurity testing for conjugated vaccines across the pipeline.

Lead the development and optimization of antigenicity- and potency-based immunoassays suitable for late-stage development and commercial use.